drugset
drugset / Trial / NCT07186621

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

NCT07186621 ↗

Phase 3 Recruiting 286 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing 302 Hospital · collabBeijing Ditan Hospital · collabEastern Hepatobiliary Surgery Hospital · collabNanfang Hospital, Southern Medical University · collabPeking University People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, randomized controlled, multicenter, phase III clinical trial

Timeline

Start
2025-07-10
Primary completion
2027-07-09
Completion
2028-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

hepatocellular carcinoma